AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
Tonix Pharmaceuticals shares rise 1.47% premarket after announcing new data on Mpox and Smallpox vaccine candidate TNX-801.
ByAinvest
Tuesday, Aug 12, 2025 7:16 am ET1min read
Tonix Pharmaceuticals Holding Corp. rose 1.47% in premarket trading, with the company announcing the presentation of new data on Mpox and Smallpox vaccine candidate TNX-801 at the Vaccine Congress 2025. Additionally, the company published Phase 3 RESILIENT Trial results of TNX-102 SL for Fibromyalgia in the peer-reviewed journal Pain Medicine, and positive preclinical data of mTNX-1700 in gastric cancer animal models in the Cancer Cell journal.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet